Trial Profile
A Phase I Study of Oral LCL 161 in Japanese Adult Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2022
Price :
$35
*
At a glance
- Drugs LCL 161 (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma
- 04 Jun 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information: JapicCTI132351).
- 20 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Jun 2016.